Tags

18F FACBC

  • Prostate Cancer Imaging with Novel PET Tracers.

    Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors.

    Published February 19, 2016
  • SNMMI 2016: Fluciclovine F18 (FACBC): An Amino Acid Tracer for the Staging of Recurrence Prostate Cancer

    San Diego, CA. USA (UroToday.com) – Coming off the recent FDA approval of Flucicovine F18 (FACBC), trade name Axumin®, it was with obvious excitement the CEO of Blue Earth Diagnostics discussed the research which lead to the recent news. Flucicovine is a synthetic amino acid based PET agent, which has been approved in men with suspected prostate cancer recurrence based on elevated PSA. 
    Published July 11, 2016
  • SNMMI 2016: Fluciclovine F18 PET-CT scanning in patients with high-risk primary prostate carcinoma

    San Diego, CA. USA (UroToday.com) – F-18 fluciclovine (FACBC) has been used as an investigational PET radiopharmaceutical to image patients with prostate cancer based on elevated amino acid transports in prostate cancers.  Its utility for disease staging has not been established for patients with high-risk primary prostate cancer. 
    Published July 11, 2016
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe